首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Novel Perspectives for Hepatitis A Virus Therapy Revealed by Comparative Analysis of Hepatitis C Virus and Hepatitis A Virus RNA Replication
【24h】

Novel Perspectives for Hepatitis A Virus Therapy Revealed by Comparative Analysis of Hepatitis C Virus and Hepatitis A Virus RNA Replication

机译:通过对丙型肝炎病毒和甲型肝炎病毒RNA复制的比较分析揭示了甲型肝炎病毒治疗的新观点

获取原文
获取原文并翻译 | 示例
           

摘要

Hepatitis A virus (HAV) and hepatitis C virus (HCV) are two positive-strand RNA viruses sharing a similar biology, but causing opposing infection outcomes, with HAY always being cleared and HCV establishing persistence in the majority of infections. To gain deeper insight into determinants of replication, persistence, and treatment, we established a homogenous cell-culture model allowing a thorough comparison of RNA replication of both viruses. By screening different human liver-derived cell lines with subgenomic reporter replicons of HAV as well as of different HCV genotypes, we found that Huh7-Lunet cells supported HAV- and HCV-RNA replication with similar efficiency and limited interference between both replicases. HAV and HCV replicons were similarly sensitive to interferon (IFN), but differed in their ability to establish persistent replication in cell culture. In contrast to HCV, HAV replicated independently from microRNA-122 and phosphatidylinositol 4-kinase IIIα and β (PI4KIII). Both viruses were efficiently inhibited by cyclosporin A and NIM811, a nonimmunosuppressive analog thereof, suggesting an overlapping dependency on cyclophilins for replication. However, analysis of a broader set of inhibitors revealed that, in contrast to HCV, HAV does not depend on cyclophilin A, but rather on adenosine-triphosphate-binding cassette transporters and FK506-binding proteins. Finally, silibinin, but not its modified intravenous formulation, efficiently inhibited HAV genome replication in vitro, suggesting oral silibinin as a potential therapeutic option for HAV infections. Conclusion'. We established a cell-culture model enabling comparative studies on RNA replication of HAV and HCV in a homogenous cellular background with comparable replication efficiency. We thereby identified new host cell targets and potential treatment options for HAV and set the ground for future studies to unravel determinants of clearance and persistence.
机译:甲型肝炎病毒(HAV)和丙型肝炎病毒(HCV)是两种具有相似生物学特性的正链RNA病毒,但造成相反的感染结果,HAY始终被清除,并且HCV在大多数感染中都具有持久性。为了更深入地了解复制,持久性和治疗的决定因素,我们建立了同质细胞培养模型,可以对两种病毒的RNA复制进行全面比较。通过用HAV的亚基因组报告子复制子以及不同HCV基因型筛选不同的人类肝脏来源的细胞系,我们发现Huh7-Lunet细胞以相似的效率和有限的两个复制之间的干扰来支持HAV-和HCV-RNA复制。 HAV和HCV复制子对干扰素(IFN)的敏感性相似,但在细胞培养物中建立持久复制的能力不同。与HCV相反,HAV独立于microRNA-122和磷脂酰肌醇4-激酶IIIα和β(PI4KIII)复制。两种病毒均被环孢菌素A和NIM811(一种非免疫抑制类似物)有效抑制,表明对亲环蛋白的复制具有重叠依赖性。但是,对更广泛的抑制剂的分析显示,与HCV相比,HAV并不依赖亲环蛋白A,而是依赖于三磷酸腺苷结合盒转运蛋白和FK506结合蛋白。最后,水飞蓟宾而不是其修饰的静脉内制剂有效地抑制了体外的HAV基因组复制,表明口服水飞蓟宾是HAV感染的潜在治疗选择。结论'。我们建立了一个细胞培养模型,可以对具有同等复制效率的同质细胞背景中的HAV和HCV RNA复制进行比较研究。因此,我们确定了新的宿主细胞靶标和HAV的潜在治疗方案,并为将来的研究奠定基础,以阐明清除率和持久性的决定因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号